Vireo Growth (VREOF) Cash from Operations Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 150.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 450.00% |
| Dec 31, 2025 | 389.54% |
| Sep 30, 2025 | -162.13% |
| Jun 30, 2025 | -49,694.90% |
| Mar 31, 2025 | -185.63% |
| Dec 31, 2024 | -1,302.11% |
| Sep 30, 2024 | -256.57% |
| Jun 30, 2024 | -100.58% |
| Mar 31, 2024 | 68.63% |
| Dec 31, 2023 | 92.49% |
| Sep 30, 2023 | 178.57% |
| Jun 30, 2023 | 152.92% |
| Mar 31, 2023 | 43.87% |
| Dec 31, 2022 | 21.51% |
| Sep 30, 2022 | 59.72% |
| Jun 30, 2022 | 75.34% |
| Mar 31, 2022 | -35.90% |
| Dec 31, 2021 | -12,398.11% |
| Sep 30, 2021 | -49.18% |
| Jun 30, 2021 | -163.16% |